ABCL-711 Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study

Autor: Yasenchak, Christopher, Kim, Jeong-AA, Hahn, Uwe, Seog Kim, Won-Seog, Fleury, Isabelle, Laribi, Kamel, Miguel Bergua Burgues, Juan, Bouabdallah, Krimo, Forward, Nicholas, Bijou, Fontanet, MacDonald, David, Portell, Craig, Ghesquieres, Herve, Nowakowski, Grzegorz, Rustia, Evelyn, Fanale, Michelle, Jie, Fei, Bartlett, Nancy
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S490-S491
Databáze: ScienceDirect
Externí odkaz: